Article
Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.
Clinical pharmacokinetics - 1 Jul 2026
Thakre Neha, Beck Denise, Saeed Ahmed M, Eckert Doerthe, Chen Mong-Jen, Liu Wei, Lon Hoi Kei, Mostafa Nael M, Mensing Sven
Abstract excerpt
BACKGROUND: Mavyret, a combination medication of glecaprevir (GLE) and pibrentasvir (PIB), is approved to treat chronic and acute hepatitis C virus (HCV) (genotypes 1-6) infection in adults and pediatric patients ≥ 3 years old. To support approval, a two-part clinical trial was conducted in adolescents (≥ 12 to < 18 years) and children (≥ 3 to < 12 years) to identify the appropriate dosage and determine the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.